1. A method for treating a patient suffering from inappropriate or excessive angiogenic activity comprising administering to a patient in need of such treatment an amount of Contact Inhibitory Factor effective to treat said disease.
2. The method of claim 1 wherein said disease is selected from solid tumors leukemias; tumor metastasis; hemangiomas, acoustic neuromas, neurofibromas, pyogenic granulomas; rheumatoid arthritis; psoriasis; ocular angiogenic diseases; diabetic retinopathy; retinopathy of prematurity; macular degeneration; corneal graft rejection; neovascular glaucoma; retrolental fibroplasia; rubeosis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation.
3. The method of claim 1, further comprising administering a pharmaceutically acceptable carrier or diluent.
4. The method of claim 3, wherein said Contact Inhibitory Factor is administered systemically.
5. The method of claim 4, wherein said Contact Inhibitory Factor is administered parenterally.
6. The method of claim 5, wherein said Contact Inhibitory Factor is administered intravenously.
7. A method for inhibiting angiogenesis in a patient comprising administering to a patient in need of such treatment an amount of Contact Inhibitory Factor effective to inhibit angiogenesis in said patient.
8. The method of claim 7, further comprising administering a pharmaceutically acceptable carrier or diluent.
9. The method of claim 8, wherein said Contact Inhibitory Factor is administered systemically.
10. The method of claim 9, wherein said Contact Inhibitory Factor is administered parenterally.
11. A method for treating a disease of excessive or abnormal stimulation of endothelial cells in a patient comprising administrating to a patient in need of such treatment an amount of Contact Inhibitory Factor effective to treat said disease.
12. The method of claim 11 wherein said disease is atherosclerosis.
13. The method of claim 11, further comprising administering a pharmaceutically acceptable carrier or diluent.
14. The method of claim 13, wherein said Contact Inhibitory Factor is administered systemically.
15. The method of claim 14, wherein said Contact Inhibitory Factor is administered parenterally.
16. A method for preventing a cancer cell from metastisizing comprising contacting said cancer cell with an amount of CIF effective to prevent said cell from metastisizing.
17. The method of claim 16 wherein said cancer cell is a solid tumor.
18. The method of claim 17 wherein said solid tumor is selected from sarcomas and carcinomas.
19. The method of claim 18 wherein said sarcomas and said carcinomas are selected from fibrosarcoma, myxosarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, endotheliosarcoma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, cervical cancer, testicular tumor, lung carcinoma, bladder carcinoma, epithelial carcinoma, melanoma, and retinoblastoma.
20. A method for preventing a cancer cell from metastasizing comprising administering to a patient in need of such treatment an amount of
(a) Contact Inhibitory Factor; and
(b) a chemotherapeutic agent,
wherein the amounts of (a) and (b) in combination are effective to prevent said cancer cell from metastasizing.
21. The method of claim 20 wherein said chemotherapeutic agent is selected from Taxol, Adriamycin, Etoposide and Gemcitabine.
22. A method for preventing a cancer cell from metastasizing in a patient who has received or is about to receive surgery to remove said cancer cell comprising administering to a patient in need of such treatment an amount of
(a) Contact Inhibitory Factor; and
(b) an agent selected from an immunotherapeutic agent and a chemotherapeutic agent;
wherein the amounts of (a) and (b) in combination are effective to prevent said cancer cell from metastasizing.
23. The method of claim 22 wherein said immunotherapeutic agent is EDM 72000.
24. The method of claim 23 wherein said chemotherapeutic agent or immunotherapeutic agent is administered before, after or substantially simultaneously with administration of said CIF.
25. The method of claim 24 wherein said chemotherapeutic agent is selected from Taxol, Adriamycin, Etoposide and Gemcitabine.
26. A pharmaceutical formulation for preventing a cancer cell from metastasizing comprising (a) Contact Inhibitory Factor; and
(b) a chemotherapeutic agent;
wherein said amounts of (a) and (b) in combination are effective to inhibit said cancer cell from metastasizing, and a pharmaceutically acceptable carrier or diluent.
27. The pharmaceutical formulation of claim 26 wherein said chemotherapeutic agent is selected from Taxol, Gemcitabine and Etoposide and Adriamycin.
28. A pharmaceutical formulation for preventing a cancer cell from metastisizing comprising
(a) Contact Inhibitory Factor; and
(b) an immunotherapeutic agent;
wherein the amounts of (a) and (b) in combination are effective to prevent said cancer cell from metastisizing.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A system for identifying a target material in a sample, the system comprising:
a first collection optic configured to collect a plurality of interacted photons that have interacted with the sample;
a tunable filter configured to filter a first plurality of interacted photons collected from the first collection optic into a plurality of wavelengths to generate filtered interacted photons;
a VIS-NIR detector configured to detect the filtered interacted photons, wherein the VIS-NIR detector generates a VIS-NIR hyperspectral image representation of the filtered interacted photons; and
a processor configured to analyze the VIS-NIR hyperspectral image of the filtered interacted photons by comparing the VIS-NIR hyperspectral image of the filtered interacted photons to a database of known VIS-NIR hyperspectral images in order to identify the presence of the target material.
2. The system of claim 1, further comprising:
a second collection optic configured to collect a second plurality of interacted photons; and
a RGB detector configured to detect the second plurality of interacted photons collected from the second collection optic, wherein the RGB detector is configured to generate a RGB image representation of the second plurality of interacted photons.
3. The system of claim 2, wherein the VIS-NIR hyperspectral image and the RGB image are generated substantially simultaneously.
4. The system of claim 1, further comprising an illumination source, wherein the illumination source is configured to provide photons that interact with the sample to generate the plurality of interacted photons.
5. The system of claim 1, wherein the tunable filter comprises a liquid crystal tunable filter, a multi-conjugate tunable filter, an acousto-optical tunable filter, a Lyot liquid crystal tunable filter, an Evans Split-Element liquid crystal tunable filter, a Solc liquid crystal tunable filter, a Ferroelectric liquid crystal tunable filter, a Fabry Perot liquid crystal tunable filter, or any combination thereof.
6. The system of claim 1, wherein the VIS-NIR detector comprises an InGaAs detector, a CMOS detector, an InSb detector, a MCT detector, an ICCD detector, a CCD detector, or any combination thereof.
7. The system of claim 1, wherein the VIS-NIR detector comprises a focal plane array.
8. The system of claim 1, further comprising a display configured to display analysis information obtained by the system to a user.
9. The system of claim 1, further comprising a user interface configured to receive one or more inputs from a user to interact with the system.
10. The system of claim 1, wherein the processor is further configured to analyze the VIS-NIR hyperspectral image generated from the filtered interacted photons by applying a chemometric technique.
11. The system of claim 10, wherein the chemometric technique comprises principle components analysis, partial least squares discriminate analysis, cosine correlation analysis, Euclidian distance analysis, k-means clustering, multivariate curve resolution, band t. entropy method, mahalanobis distance, adaptive subspace detector, spectral mixture resolution, Bayesian fusion or any combination thereof.
12. The system of claim 1, wherein the system is housed in a portable or handheld unit.
13. A method for identifying a target material in a sample, the method comprising:
collecting a plurality of interacted photons from the sample, wherein the plurality of interacted photons have interacted with the sample;
directing a first plurality of interacted photons through a filter to generate a first plurality of filtered photons, wherein the filter separates the first plurality of interacted photons into a plurality of wavelengths;
detecting the first plurality of filtered photons with a VIS-NIR hyperspectral image detector, generating a VIS-NIR hyperspectral image of the first plurality of filtered photons; and
analyzing the VIS-NIR hyperspectral image of the filtered interacted photons by comparing the VIS-NIR hyperspectral image of the filtered interacted photons to a database of known hyperspectral images to identify the presence of the target material.
14. The method of claim 13, further comprising:
collecting a second plurality of interacted photons;
detecting the second plurality of interacted photons with a RGB detector, and
generating a RGB image representation of the second plurality of interacted photons.
15. The method of claim 14, wherein the VIS-NIR hyperspectral image of the filtered interacted photons and the RGB image are generated simultaneously.
16. The method of claim 14, further comprising illuminating the sample with an illumination source, wherein the illumination source provides photons that interact with the sample to generate the second plurality of interacted photons.
17. The method of claim 13, further comprising illuminating the sample with an illumination source wherein, the illumination source provides photons that interact with the sample to generate the first plurality of interacted photons.
18. The method of claim 13, wherein analyzing the VIS-NIR hyperspectral image further comprises applying a chemometric technique.
19. A system for identifying an target material in a sample, the system comprising:
an illumination source configured to provide photons that interact with the sample to generate a plurality of interacted photons;
a first collection optic configured to collect a first plurality of interacted photons where the first plurality of interacted photons includes photons that have interacted with the sample;
a second collection optic configured to collect a second plurality of interacted photons where the second plurality of interacted photons includes photons that have interacted with the sample;
a tunable filter configured to filter the first plurality of interacted photons collected from the first collection optic into a plurality of wavelengths to generate filtered interacted photons;
a VIS-NIR detector configured to detect the filtered interacted photons, wherein the VIS-NIR detector generates a VIS-NIR hyperspectral image of the filtered interacted photons;
a RGB detector configured to detect the second plurality of interacted photons, wherein the RGB detector generates a RGB image representation of the second plurality of interacted photons; and
a processor configured to analyze the VIS-NIR hyperspectral of the filtered interacted photons and compare the VIS-NIR hyperspectral image of the filtered interacted phtons to a database of known VIS-NIR hyperspectral images in order to identify the target material.
20. The system of claim 19 wherein the VIS-NIR hyperspectral image and the RGB image are generated simultaneously.
21. The system of claim 19, wherein the tunable filter comprises a liquid crystal tunable filter, a multi-conjugate tunable filter, an acousto-optical tunable filter, a Lyot liquid crystal tunable filter, an Evans Split-Element liquid crystal tunable filter, a Solc liquid crystal tunable filter, a Ferroelectric liquid crystal tunable filter, a Fabry Perot liquid crystal tunable filter, or any combination thereof.
22. The system of claim 19, wherein the VIS-NIR detector comprises a InGaAs detector, a CMOS detector, an InSb detector, a MCT detector, an ICCD detector, a CCD detector, or any combination thereof.
23. The system of claim 19, wherein the VIS-NIR detector comprises a focal plane array.
24. The system of claim 19, further comprising a display configured to display VIS-NIR hyperspectral analysis information, RGB image information, or any combination thereof obtained by the system to a user.
25. The system of claim 19, further comprising a user interface configured to receive one or more inputs from a user to interact with the system.
26. The system of claim 19, wherein the processor is further configured to analyze the VIS-NIR hyperspectral image of the filtered interacted photons by applying a chemometric technique.
27. The system of claim 26, wherein the chemometric technique comprises: principle components analysis, partial least squares discriminate analysis, cosine correlation analysis, Euclidian distance analysis, k-means clustering, multivariate curve resolution, band t. entropy method, mahalanobis distance, adaptive subspace detector, spectral mixture resolution, Bayesian fusion or any combination thereof.
28. The system of claim 19, wherein the system is housed in a portable or handheld unit.